Stockscreener 앱 받기
83.86
0.02%
0.01
시간 외 거래:
83.86
전일 마감가:
$83.85
열려 있는:
$83.87
하루 거래량:
2.32M
Relative Volume:
0.66
시가총액:
$8.88B
수익:
$18.07M
순이익/손실:
$-496.39M
주가수익비율:
-16.34
EPS:
-5.1333
순현금흐름:
$-419.52M
1주 성능:
-0.04%
1개월 성능:
+128.51%
6개월 성능:
+63.42%
1년 성능:
+176.78%
1일 변동 폭
$83.84
$83.98
1주일 범위
$83.64
$84.00
52주 변동 폭
$25.83
$84.00
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
명칭
Crinetics Pharmaceuticals Inc
전화
858-450-6464
주소
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
83.86 | 8.87B | 18.07M | -496.39M | -419.52M | -5.1333 |
VRTX
Vertex Pharmaceuticals Inc
|
490.39 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
695.18 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
872.23 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.86 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.41 | 37.17B | 4.29B | 577.22M | 641.34M | 4.2086 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-12 | 업그레이드 | Goldman | Neutral → Buy |
| 2025-07-10 | 개시 | Goldman | Neutral |
| 2025-03-25 | 개시 | Stifel | Buy |
| 2025-02-11 | 개시 | TD Cowen | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Peer Perform |
| 2025-01-22 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-01-16 | 개시 | Morgan Stanley | Overweight |
| 2023-12-21 | 개시 | Jefferies | Hold |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-31 | 개시 | Oppenheimer | Outperform |
| 2023-04-24 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Robert W. Baird | Outperform |
| 2021-11-30 | 개시 | JMP Securities | Mkt Outperform |
| 2021-11-23 | 개시 | Evercore ISI | Outperform |
| 2021-06-18 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-23 | 개시 | ROTH Capital | Buy |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2018-08-13 | 개시 | JP Morgan | Neutral |
| 2018-08-13 | 개시 | Leerink Partners | Outperform |
| 2018-08-13 | 개시 | Piper Jaffray | Overweight |
모두보기
Crinetics Pharmaceuticals Inc 주식(CRNX)의 최신 뉴스
CRNX Downgraded by UBS -- Price Target Raised to $85.00 - GuruFocus
UBS downgrades Crinetics stock rating on Vertex acquisition By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals Inc - TradingKey
CRNX|Crinetics Pharmaceuticals Inc|Price:83.865|Chg%:+0.135 - TradingKey
Crinetics Pharmaceuticals Inc (CRNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Crinetics Pharmaceuticals Inc (CRNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Crinetics Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CRNX - TradingView
Crinetics Pharmaceuticals Inc (CRNX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Crinetics Pharmaceuticals Inc (CRNX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—CRNX, SLP, NCSM, and PASG - Morningstar
Vertex was sole bidder in high-premium Crinetics acquisition - BioPharma Dive
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity - TipRanks
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunit - Benzinga
How Crinetics Pharmaceuticals Inc. (CRNX) Affects Rotational Strategy Timing - Stock Traders Daily
Vertex was only bidder for Crinetics in year’s second-highest M&A premium - Endpoints News
Vertex-Crinetics Pharmaceuticals deal faces Australian review - MLex
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NY - Supply Chain Digital
Crinetics Pharmaceuticals stock trades up to $83.90 as Everyday Advocacy resource launches, Crinetics - Traders Union
Crinetics Pharmaceuticals (CRNX) Piper Sandler 36th Annual Healthcare Conference summary - Quartr
CRNX: Pipeline advances in acromegaly, CAH, and NETs, with strong financial runway into 2030 - TradingView
Vertex, Crinetics Pharmaceuticals filed US premerger notifications July 20 - MLex
Crinetics Pharmaceuticals (NASDAQ: CRNX) backs $85-per-share cash sale to Vertex - Stock Titan
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders? - TradingView
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Shareholder Alert: Ademi LLP investigates whether Crinetics - GlobeNewswire
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why - Sahm
Crinetics Pharmaceuticals (CRNX) Q2 2025 earnings summary - Quartr
Crinetics Pharmaceuticals (CRNX) R&D Day 2025 Summary - Quartr
Crinetics Pharmaceuticals (CRNX) Proxy filing Summary - Quartr
Monteverde investigates Element Solutions, Crinetics, and AstroNova sales - scanx.trade
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--ESI, CRNX, SOLS, and PATK - Sahm
Crinetics Pharmaceuticals (CRNX) Stock Looks Fully Valued While Returns Stay Very Strong - Sahm
Crinetics Pharmaceuticals (CRNX) Looks Fully Valued As Vertex Agrees $85 Per Share Deal - Sahm
Halper Sadeh LLC is Investigating Whether ESI, CRNX, SOLS are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal - Yahoo Finance
After Crinetics' $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story? - Benzinga
Crinetics Pharmaceuticals stock hits all-time high at 83.77 USD By Investing.com - Investing.com India
Crinetics Pharmaceuticals stock hits all-time high at 83.77 USD - Investing.com
Crinetics Pharmaceuticals Acquired by Fortress Biotech for $10 Billion - BioBuzz
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals - Yahoo Finance
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy? - webull.com
Truist raises Vertex stock price target to $560 on Crinetics deal - Investing.com UK
Truist raises Vertex stock price target to $560 on Crinetics deal By Investing.com - Investing.com India
Drugmaker Vertex spends $10B to buy biotech firm to expand rare-disease offerings - Post and Courier
Vertex Pharmaceuticals (VRTX) Announces $10B Acquisition of Crin - GuruFocus
Vertex Pharmaceuticals (VRTX) Announces $10B Acquisition of Crinetics Pharmaceuticals - GuruFocus
Vertex to buy Crinetics for $10 billion to expand rare-disease business - MSN
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse - TradingView
Crinetics Pharmaceuticals Announces Merger Agreement and Non-Compete Agreements With Key Executives - Minichart
Crinetics Pharmaceuticals Inc. (CRNX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Crinetics Pharmaceuticals Inc (CRNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.41%
2.56%
자본화:
|
볼륨(24시간):